Absorption kinetics of topical clindamycin preparations.
Systemic clindamycin absorption was examined in 12 male Caucasians without acne who received 1 ml of Cleocin-T and 1 ml of 1 per cent clindamycin HCl in Vehicle-N (Neutrogena) applied topically the face every 12 h for 4 days according to a crossover design. In a separate phase clindamycin phosphate was administered by an IV infusion of 300 mg over 10 min. Systemic absorption was much higher with clindamycin in Vehicle-N than with Cleocin-T. Absolute bioavailability calculated from cumulative urinary excretion and serum AUCs were in good agreement and averaged 1.7 per cent and 7.5 per cent for Cleocin-T and clindamycin in Vehicle-N, respectively. Peak serum concentrations ranged from less than 0.5 ng ml-1 to 6 ng ml-1 for Cleocin-T and from 4-20 ng ml-1 for clindamycin in Vehicle-N. Absorption profiles indicated zero order absorption with Cleocin-T. No appreciable systemic accumulation from the repeated topical applications was noted. Systemic exposure to clindamycin from these formulations is minimal.
Eller
M G
MG
Clinical Pharmacokinetics Unit, Upjohn Company, Kalamazoo, MI 49001.
Smith
R B
RB
Phillips
J P
JP
D000287:Administration, Topical; D000328:Adult; D002981:Clindamycin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D011863:Radioimmunoassay
D002981:Clindamycin